The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
April 30th 2025
Nipocalimab the first and only FcRn blocker approved in anti-acetylcholine receptor– or anti-muscle-specific kinase adults and children with generalized myasthenia gravis.
Is Medicare Overpaying for Specialty Medications Under Part B?
July 22nd 2013The 10 highest-expenditure Medicare Part B drugs, all of which are classified as specialty medications, accounted for 45% of Part B spending in 2010, according to a report from the US Government Accountability Office highlighted in recent congressional testimony.
Read More
Regence Selects Walgreens to Provide Specialty Infusion Medication Services for Members
July 22nd 2013Walgreens Infusion Services and Regence, an affiliation of health care plans in the Pacific Northwest/Mountain State region, recently entered into an agreement to help lower overall medical costs for specialty infusion patients in Idaho, Oregon, Utah, and Washington.
Read More
Elotuzumab Combination Therapy Shows Promise in Previously Treated Multiple Myeloma
July 20th 2013Patients with previously treated multiple myeloma responded well to therapy with the monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone, with a high objective response rate and longer progression-free survival (PFS) in those who received the dose being taken into phase III studies.
Read More
SPAARx Questions Language in HIPAA Final Rule
July 16th 2013In a recent letter to HHS, the Specialty Pharmacy Association of America expressed its concerns about the impact of the HIPAA Final Rule on remuneration for Medication Therapy Management and specialty pharmacy services and on interaction with patients through social media platforms.
Read More
NASP to Develop Pharmacy Practice Parameters for Specialty Pharmacy Therapeutic Categories
July 16th 2013The National Association of Specialty Pharmacy (NASP) announced it will begin developing pharmacy practice parameters in approximately 20 specialty pharmacy therapeutic categories this year.
Read More
Drug Approvals to Treat Neglected Diseases Have Nearly Doubled
July 12th 2013A new study released by the Tufts Center for the Study of Drug Development reports that annual drug approvals for neglected diseases have nearly doubled since 2000, and patient access to these therapies has improved markedly.
Read More
FDA Approves New Treatment for NSCLC in Patients with Certain EGFR Mutations
July 12th 2013The FDA today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.
Read More
FDA Publishes Draft Guidance on Gene and Cell Therapy Clinical Trials
July 9th 2013Many of the types of drugs addressed by the guidance document could be categorized as specialty drugs because they require special handling, frequent dosing adjustments, and intensive clinical monitoring of adverse effects.
Read More
Pharmacy-Based Clinical Trial Recruitment: A Potential New Role for the Pharmacist?
July 2nd 2013Research presented on June 25, 2013, at the Drug Information Association (DIA) 2013 49th Annual Meeting could trigger a paradigm shift in clinical trial patient recruitment and could change the way pharmacists engage with patients as new drugs make their way through the FDA approval process.
Read More
Diplomat Specialty Pharmacy Receives Compounding Pharmacy Accreditation from PCAB
June 27th 2013Diplomat Specialty Pharmacy, the country's largest independent specialty pharmacy servicing the needs of patients and physicians nationwide, is pleased to announce the company's compounding pharmacy has been accredited by the Pharmacy Compounding Accreditation Board (PCAB).
Read More
Avella Specialty Pharmacy: Overcoming Oncology Adherence Barriers
June 18th 2013Specialty Pharmacy Times sat down to talk with Dr. Eric Sredzinski about the controversial topic of pricing for oncology medications, as well as common patient reimbursement hurdles and Avella's technologically savvy efforts to break down patient adherence barriers.
Read More